Thiotepa toxicity
WebFeb 6, 2024 · Increased risk of toxicity. Concomitant therapy not recommended until patient recovers from previously induced myelosuppression. Succinylcholine. Thiotepa may … WebNational Center for Biotechnology Information
Thiotepa toxicity
Did you know?
WebThe use of thiotepa is invariably associated with haematological toxicity, while extra-haematological toxicity is absent or mild in the commonly used posologies. Myelosuppression is the dose-limiting toxicity in its use in standard chemotherapy. The Applicant proposed an indication for Tepadina as conditioning treatment prior to … WebApr 1, 2008 · Thiotepa shows clinical activity against a variety of neoplasms, including lymphoma, ovarian carcinoma, breast carcinoma, and Wilms' tumor. With standard total …
WebApr 14, 2024 · As bone marrow toxicity and infections were the major toxicities observed in ic-VDC/IE, dose reductions instead of dose delays should be considered when these side effects occur . ... In rhabdomyosarcoma, the use of thiotepa and melphalan in Japan has resulted in a 3-year PFS > 50% for ARMS [20,52]. WebNeurotoxicity is more likely when thiotepa is administered IT, with symptoms similar to MTX and Ara-C, including a mild, reversible chemical meningitis and, in rare cases, a transient or persistent myelopathy. View chapter Purchase book Chemotherapy in chronic kidney disease and dialysis SABINE KARAM, ... ILYA GLEZERMAN, in Onco-Nephrology, 2024
WebThiotepa, a highly lipophilic, alkylating agent, and/or its active metabolites may be excreted in part via skin in patients receiving high-dose therapy. We present a case of cutaneous … WebThiotepa (also known as Thioplex ®) is an anticancer medicine. It is a clear liquid given by vein (IV). Thiotepa can pose a health hazard to caregivers. All caregivers should take …
Webdeferiprone, thiotepa. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be …
WebApr 7, 2024 · • Thiotepa may cause severe marrow suppression, and high doses may cause marrow ablation with resulting infection or bleeding. Monitor hematologic laboratory parameters. homographs 3rd gradeWeb5.3 Cutaneous Toxicity Thiotepa and/or its active metabolites may be excreted in part via skin patients receiving high-dose therapy. Treatment with thiotepa may cause skin discoloration, pruritus, blistering, desquamation, and peeling that may be more severe in the groin, axillae, skin folds, in the neck area, and under dressings. homographs 2nd gradeWebObjectives: The primary objective of this prospective feasibility study was to determine the MED of thiotepa (5mg/kg) in combination with reduced-dose busulfan, fludarabine or cyclophosphamide, and rATG required to achieve engraftment in >90% of HSCT recipients for non-malignant disorders with acceptable toxicity. historical filmsWebJan 4, 2024 · The most reliable guide to thiotepa toxicity is the white blood cell count. If this falls to 3000 or less, the dose should be discontinued. Another good index of thiotepa toxicity is the platelet count; if this falls to … homographs for fairWebFeb 13, 2024 · Toxicity to the gastrointestinal and central nervous system is dose-limiting and the maximum tolerated dose (MTD) of thiotepa is between 1005 and 1125 mg/m 2 [7, … homographs 5th gradeWebNov 2, 2015 · Thiotepa-related toxicity was mainly digestive, whereas sinusoidal obstruction syndrome was the main toxicity observed after Bu–Mel. The 3-year event-free survival of this cohort was 37.3% (21.3 ... homographs for closeWebToxicity of tandem high-dose chemotherapy and autologous stem cell transplantation using carboplatin-thiotepa-etoposide and cyclophosphamide-melphalan regimens for malignant brain tumors in children and young adults J Neurooncol. 2014 Dec;120 (3):507-13. doi: 10.1007/s11060-014-1576-1. Epub 2014 Aug 10. Authors homographs for bow